Challenges and Key Considerations of the Enhanced Permeability and Retention Effect for Nanomedicine Drug Delivery in Oncology
Uma Prabhakar(AstraZeneca (United Kingdom)), David C. Blakey(Unknown), Omid C. Farokhzad(Brigham and Women's Hospital), Alberto Gabizón(University of California, San Francisco), Eva M. Sevick‐Muraca(Brown Foundation), Hiroshi Maeda(Kumamoto University), William C. Zamboni(AstraZeneca (United Kingdom)), Piotr Grodzinski(National Institutes of Health), Simon T. Barry(AstraZeneca (Singapore))
Cited by 1,460
Related Papers
A new concept for macromolecular therapeutics in cancer chemotherapy: mechanism of tumoritropic accumulation of proteins and the antitumor agent smancs.
|PubMed|1986|6.8k
Tumor vascular permeability and the EPR effect in macromolecular therapeutics: a review
|Journal of Controlled Release|2000|6.5k
Cancer nanomedicine: progress, challenges and opportunities
|Nature reviews. Cancer|2016|5.6k
The EPR effect: Unique features of tumor blood vessels for drug delivery, factors involved, and limitations and augmentation of the effect
|Advanced Drug Delivery Reviews|2010|3.5k
The enhanced permeability and retention (EPR) effect in tumor vasculature: the key role of tumor-selective macromolecular drug targeting
|Advances in Enzyme Regulation|2001|2.5k